8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 14, 2007

SALIX PHARMACEUTICALS, LTD.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

000-23265	94-3267443
(Commission File Number)	(IRS Employer ID Number)

1700 Perimeter Park Drive, Morrisville, North Carolina	27560
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (919) 862-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On February 14, 2007, Salix Pharmaceuticals, Ltd. issued a press release announcing that it will report fourth quarter 2006 and fiscal year ended 2006 financial results before the market opens on Wednesday, February 28, 2007. A copy of this press release is attached as Exhibit 99.1.

Additionally, on February 14, 2007, Salix Pharmaceuticals, Ltd. issued a press release announcing that it will present at the 19^th Annual Roth Capital Partners Growth Stock Conference in Laguna Niguel, California, on Wednesday, February 21, 2007, at 2:00 p.m., ET. A copy of this press release is attached as Exhibit 99.2.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1	Press release dated February 14, 2007.
99.2	Press release dated February 14, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	SALIX PHARMACEUTICALS, LTD.
Date: February 14, 2007
	/s/ Adam C. Derbyshire
	Adam C. Derbyshire
	Senior Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:	Adam C. Derbyshire	Mike Freeman
	Senior Vice President and Chief Financial Officer	Executive Director, Investor Relations and Corporate Communications
	919-862-1000	919-862-1000

SALIX PHARMACEUTICALS ANNOUNCES

4Q2006 AND FY2006 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST

RALEIGH, NC, February 14, 2007 – Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year ended December 31, 2006 financial results before the market opens on Wednesday, February 28, 2007.

The Company will host a conference call at 9:00 a.m. ET, on Wednesday, February 28, 2007. Interested parties can access the conference call by way of web cast or telephone. The live web cast will be available at http://www.salix.com. A replay of the web cast will be available at the same location.

The telephone numbers to access the conference call are (800) 479-9001 (U.S. and Canada) or (719) 457-2618 (international.) The access code for the call is 5114993. A replay of the call will be available from 12:00 noon ET. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international.) The access code for the replay is 5114993.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix also markets XIFAXAN^®, VISICOL^®, OSMOPREP™, AZASAN^®, ANUSOL-HC^® and PROCTOCORT^®. In August 2006, the FDA approved MOVIPREP^® for bowel cleansing prior

to colonoscopy, and we intend to launch the product in mid-fourth quarter 2006. Balsalazide tablets, Granulated Mesalamine, SANVAR^® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Salix trades on the NASDAQ Market under the ticker symbol “SLXP.”

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.

EX-99.2

Exhibit 99.2

FOR IMMEDIATE RELEASE

Contact:	Adam C. Derbyshire	Mike Freeman
	Senior Vice President and Chief Financial Officer	Executive Director, Investor Relations and Corporate Communications
	919-862-1000	919-862-1000

SALIX PHARMACEUTICALS TO PRESENT AT

ROTH CAPITAL PARTNERS CONFERENCE

RALEIGH, NC, February 14, 2007 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 19th Annual Roth Capital Partners Growth Stock Conference in Laguna Niguel, CA on Wednesday, February 21, 2007 at 2:00 p.m. ET.

Interested parties can access a live audio web cast of this presentation at http://www.salix.com. A replay of this presentation will be available at the same location.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix markets COLAZAL^®, XIFAXAN^®, OSMOPREP™, VISICOL^®, MOVIPREP^® , AZASAN^®, ANUSOL-HC^® and PROCTOCORT^®. Balsalazide tablets, Granulated Mesalamine, SANVAR^® (600 ug vials vapreotide acetate powder) and Xifaxan for additional indications are under development.

Salix trades on the NASDAQ Global Market under the ticker symbol “SLXP”.

For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.